The Alluvium Study
A phase 2, multicenter, randomized, double masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema.
The study’s primary focus is on evaluating the efficacy of RO7200220, comparing its performance against an active comparator, ranibizumab, a standard treatment. Comprehensive assessments of safety and tolerability ensure that intravitreal administration of RO7200220 is both effective and well-tolerated by patients. This study is 18 months long.